Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.37
$1.61
$0.44
$2.09
$341.54M1.61.25 million shs1.17 million shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
$3.41
$1.79
$6.30
$524.84M1.12N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.22
+2.6%
$0.31
$0.16
$3.39
$22.57M0.324.87 million shs3.21 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
$3.56
$708K2.34455,220 shs400 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
0.00%-9.27%-11.04%-19.41%+208.56%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%0.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%-13.72%-13.75%-49.77%-84.70%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.37
$1.61
$0.44
$2.09
$341.54M1.61.25 million shs1.17 million shs
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$3.41
$3.41
$1.79
$6.30
$524.84M1.12N/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$0.22
+2.6%
$0.31
$0.16
$3.39
$22.57M0.324.87 million shs3.21 million shs
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$0.02
$0.02
$0.25
$3.56
$708K2.34455,220 shs400 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
0.00%-9.27%-11.04%-19.41%+208.56%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
0.00%0.00%0.00%0.00%0.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%-13.72%-13.75%-49.77%-84.70%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00%0.00%0.00%0.00%-14.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$6.25356.20% Upside
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
1.00
SellN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.00
Hold$4.501,933.44% Upside
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SQZ, OTLK, LCTX, and OPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Reiterated RatingBuy$3.00
4/28/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Initiated CoverageBuy$9.00
3/27/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Reiterated RatingSell (E+)
3/25/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Boost Price TargetBuy$3.00 ➝ $4.00
3/24/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Reiterated RatingBuy$9.00
3/11/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Lower Price TargetBuy$10.00 ➝ $6.00
3/6/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Reiterated RatingBuy
3/6/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Boost Price TargetBuy$2.00 ➝ $3.00
2/18/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Reiterated RatingNeutral
2/18/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Reiterated RatingNeutral
2/9/2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Reiterated RatingBuy$2.00
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$14.56M23.46N/AN/A$0.19 per share7.21
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
$25K20,993.46N/AN/A($1.31) per share-2.60
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.35M17.15N/AN/A($0.60) per share-0.37
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
$18.16M0.04N/AN/A$1.94 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$63.53M-$0.12N/AN/AN/A-436.47%-76.13%-35.53%5/12/2026 (Estimated)
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
-$162.79MN/AN/AN/AN/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$62.42M-$2.62N/AN/AN/AN/AN/A-293.47%5/14/2026 (Estimated)
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
-$79.46M-$2.61N/AN/AN/A-369.96%-119.83%-59.90%N/A

Latest SQZ, OTLK, LCTX, and OPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q2 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.12N/AN/AN/A$4.39 millionN/A
5/12/2026Q1 2026
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$0.02N/AN/AN/A$3.60 millionN/A
3/5/2026Q4 2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$0.07$0.0040+$0.0740$0.0040$1.96 million$6.61 million
2/17/2026Q1 2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.17-$0.22-$0.05-$0.38$3.14 million($1.21) million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
5.20
5.20
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
N/A
0.22
0.22
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.35
0.28
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
N/A
3.50
3.50

Institutional Ownership

CompanyInstitutional Ownership
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
55.95%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
38.51%

Insider Ownership

CompanyInsider Ownership
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
26.80%
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
3.20%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80%
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
16.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
60249.30 million182.49 millionNot Optionable
Opthea Limited Unsponsored ADR stock logo
OPT
Opthea
8153.91 million165.53 millionNot Optionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
20104.61 million101.69 millionOptionable
SQZ Biotechnologies stock logo
SQZ
SQZ Biotechnologies
1,62029.49 million24.77 millionNot Optionable

Recent News About These Companies

Arsenal Yards attracts another life sciences tenant
SQZB SQZ Biotechnologies Company - Seeking Alpha
Serica Energy shares drop as Triton suspended until mid-March
Serica Energy says 2025 outlook is ‘promising'
SQZ Biotechnologies Co Ordinary Shares
SQZ Biotechnologies Company (SQZB)
Sqz Bio (SQZB) Earnings Dates & Reports
VC funding update: who raised money in March?
SQZB SQZ Biotechnologies Company

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.37 0.00 (0.00%)
Closing price 05/8/2026 04:10 PM Eastern
Extended Trading
$1.37 +0.00 (+0.15%)
As of 05/8/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Opthea stock logo

Opthea NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$0.22 +0.01 (+2.60%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$0.22 +0.00 (+1.22%)
As of 05/8/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

SQZ Biotechnologies stock logo

SQZ Biotechnologies NYSE:SQZ

$0.02 0.00 (0.00%)
As of 05/8/2026

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.